Lung Non-Small Cell Carcinoma

Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. PF-06463922 showed inhibition of kinase activity, cell viability and tumor growth in wild-type, G2032R and L2026M muta… (full text at CIViC)

PMID 25733882 · Zou et al., 2015 · Open in CIViC

In a phase 1-2 trial (NCT03093116), the ROS1/ALK/NTRK inhibitor repotrectinib demonstrated efficacy in NSCLC with ROS1 fusions. In the 56 patients who had previously received one ROS1 tyrosine kinase… (full text at CIViC)

PMID 38197815 · Drilon et al., 2024 · Open in CIViC

The TRUST-I study (NCT04395677) was a phase II, multicenter, single-arm, open-label trial conducted in China to evaluate taletrectinib for ROS1 fusion-positive, locally advanced, or metastatic non-sma… (full text at CIViC)

PMID 38822758 · Li et al., 2024 · Open in CIViC

Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib.

PMID 25688157 · Song et al., 2015 · Open in CIViC

Ba/F3 cells expressing CD74–ROS1 G2101A showed resistance to crizotinib, compared with those expressing wild-type CD74–ROS1, and were sensitive to foretinib.

PMID 25688157 · Song et al., 2015 · Open in CIViC

Preclinical study of PF-06463922 in NSCLC in-vitro, in-vivo and in enzyme assays. BaF3 cells expressing CD74-ROS1 L2026M were more resistant to crizotinib treatment than wildtype CD74-ROS1 in both cel… (full text at CIViC)

PMID 25733882 · Zou et al., 2015 · Open in CIViC

Ba/F3 cells expressing CD74–ROS1 L2026M mutation showed resistance to crizotinib (~10 fold higher IC50 value), compared with those expressing wild-type CD74–ROS1; however, showed similar sensitivity t… (full text at CIViC)

PMID 25688157 · Song et al., 2015 · Open in CIViC

The L2155S mutation in ROS1 was identified in the HCC78CR1, -2 and -3 cell lines which harbor the SLC34A2–ROS1 rearrangement and in 2 patients with NSCLC with progressive disease following crizotinib … (full text at CIViC)

PMID 25688157 · Song et al., 2015 · Open in CIViC

A patient with ROS1 fusion-positive NSCLC was treated with crizotinib for 26 months achieved tumor response (-64%). After tumor progression, a rebiopsy sample was obtained and revealed ROS1 R2033N mut… (full text at CIViC)

PMID 26673800 · Drilon et al., 2016 · Open in CIViC

Study describes the expansion of a phase 1 study of crizotinib in a 50 patient cohort with advanced NSCLC and exhibiting ROS1 rearrangements. Among the 50 patients 72% exhibited a response (3 complete… (full text at CIViC)

PMID 25264305 · Shaw et al., 2014 · Open in CIViC

In a retrospective study, authors identified 16 ROS1 fusion-positive lung cancer patients who underwent a total of 17 repeat biopsies following disease progression on crizotinib ROS1 resistance mutat… (full text at CIViC)

PMID 29333528 · Gainor et al., 2017 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing S1986F mutation in the ROS1 portion of the EZR-ROS1 fusion protein was associated with resistance to crizotinib treatment (IC50: 116 nM), as compared… (full text at CIViC)

PMID 27401242 · Facchinetti et al., 2016 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing a S1986Y mutation in the ROS1 portion of the EZR-ROS1 fusion protein was associated with resistance to crizotinib treatment (IC50: 125 nM), as compar… (full text at CIViC)

PMID 27401242 · Facchinetti et al., 2016 · Open in CIViC

A patient with ROS1 fusion-positive NSCLC was treated with crizotinib and led to durable response (-75%) over 22 months. After tumor progression, a rebiopsy sample was obtained and revealed ROS1 S1986… (full text at CIViC)

PMID 27401242 · Facchinetti et al., 2016 · Open in CIViC

Expression level of RRM1 was evaluated in 61 NSCLC samples with RT-qPCR. Low expression of RRM1 was associated with longer median survival time (13.9 versus 10.9 months, P = 0.039). However, RRM1 expr… (full text at CIViC)

PMID 16980606 · Ceppi et al., 2006 · Open in CIViC

In this study, 229 tumors were analyzed for RRM1 expression. This resulted in 146 that were negative for RRM1 expression and 83 that were positive. These tumors were studied for a relationship between… (full text at CIViC)

PMID 24647522 · Dong et al., 2014 · Open in CIViC

In a retrospective study of 34 non-small cell lung cancer patients, a lung adenocarcinoma patient with SCN8A deleterious Q427* mutation, treated with pembrolizumab monotherapy, was associated with a d… (full text at CIViC)

PMID 25765070 · Rizvi et al., 2015 · Open in CIViC

In patient with lung adenocarcinoma an SDC4-NRG1 gene fusion was detected. Integrative genome analysis was used to assess the potential functional significance of the detected gene fusion, prioritizin… (full text at CIViC)

PMID 28950338 · Jones et al., 2017 · Open in CIViC

In an evaluation of a patient and never smoker with crizotinib-sensitive lung adenocarcinoma, an SDC4-ROS1 rearrangement was identified using comprehensive genomic profiling. The patient attained a de… (full text at CIViC)

PMID 25922291 · Le et al., 2015 · Open in CIViC

Case report describing a patient with NSCLC and EGFR(ex25)::Intergenic Region of SEC61G(breakpoint 32 aa downstream of SEC61G) fusion and concurrent EGFR amplification with treatment response to a com… (full text at CIViC)

PMID 34342091 · Zhang et al., 2021 · Open in CIViC

A 42 year old nonsmoker with metastatic lung adenocarcinoma that was wild-type for EGFR, KRAS, ROS1, and ALK, was found to have re-arranged NRG1. Treatment with afatanib resulted in rapid symptomatic … (full text at CIViC)

PMID 28502724 · Gay et al., 2017 · Open in CIViC

Of the 28 individuals that received 30 treatments containing gemcitabine or etoposide, only 13 of them showed underexpression of SMAD4. Treatment with DNA topoisomerase inhibitors, especially gemcitab… (full text at CIViC)

PMID 28577946 · Ziemke et al., 2017 · Open in CIViC

In patients with lung adenocarcinoma, those with loss-of-function mutations in SMARCA4 had worse overall survival than those with only missense or no mutations.

PMID 24658004 · Jelinic et al., 2014 · Open in CIViC

AURKA activity is essential in NSCLC cells lacking SMARCA4/BRG1. In these cells, RNAi-mediated depletion or chemical inhibition of AURKA induces apoptosis and cell death in vitro and in xenograft mous… (full text at CIViC)

PMID 28102363 · Tagal et al., 2017 · Open in CIViC

Preclinical evidence showing that SMARCA4 inactivation results in downregulation of Cyclin D1 in NSCLC cells and confers sensitivity of such to CDK4/6 inhibitors. SMARCA4 loss is synthetic letha with … (full text at CIViC)

PMID 30718506 · Xue et al., 2019 · Open in CIViC

SMARCA4 expression was determined with gene expression microarray in 133 patients. Reduced overall survival was observed in patients with low SMARCA4 expression compared to intermediate (P<0 .001) or … (full text at CIViC)

PMID 26671993 · Bell et al., 2016 · Open in CIViC

SMARCA4 expression was determined with gene expression microarray in 133 patients. Improved five-year disease-specific survival (DSS) was noted only in patients with low SMARCA4 expression when treate… (full text at CIViC)

PMID 26671993 · Bell et al., 2016 · Open in CIViC

Activation of the Hh pathway was found in both models of EGFR-mutated and EGFR-WT NSCLC cell line resistant to EGFR-TKIs. In EGFR-WT NSCLC cell lines resistant to EGFR inhibitors, the combined inhibit… (full text at CIViC)

PMID 26124204 · Della Corte et al., 2015 · Open in CIViC

Activation of the Hh pathway was found in both models of EGFR-mutated and EGFR-WT NSCLC cell line resistant to EGFR-TKIs. In EGFR-WT NSCLC cell lines resistant to EGFR inhibitors, the combined inhibit… (full text at CIViC)

PMID 26124204 · Della Corte et al., 2015 · Open in CIViC

In 1378 cases of NSCLC screened for NTRK1 rearrangements, 2 were identified (frequency 0.1%). One patient with SQSTM1-NTRK1 was treated with entrectinib in a phase 1 study. The patient had resolution … (full text at CIViC)

PMID 26565381 · Farago et al., 2015 · Open in CIViC

Two phase I studies in patients with advanced or metastatic solid tumors, including patients with active central nervous system (CNS) disease. Here, we summarize the overall safety and report the anti… (full text at CIViC)

PMID 28183697 · Drilon et al., 2017 · Open in CIViC

In a retrospective analysis of 567 non-squamous, non-small cell lung cancer patients, Exon 1-2 mutations in STK11 were significantly associated with shorter OS (24 vs. 69 months) also after multivaria… (full text at CIViC)

PMID 26625312 · Pécuchet et al., 2017 · Open in CIViC

A clinical trial comparing selumetinib and docetaxel vs. docetaxel and placebo in KRAS mutant NSCLC was recapitulated in mice. Tumors were induced in lung epithelium by nasal instillation of CRE-beari… (full text at CIViC)

PMID 22425996 · Chen et al., 2012 · Open in CIViC

Preclinical study in 5 NSCLC cell lines. Two LKB1 (STK11) mutant cell lines had higher basal levels of mTOR activity (pS6K and p4EBP1 levels) but were not more sensitive to mTOR inhibitors (everolimus… (full text at CIViC)

PMID 26027660 · Xiao et al., 2015 · Open in CIViC

STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype.

PMID 15021901 · Carretero et al., 2004 · Open in CIViC

STK11 is mutated and inactivated in 20-30% of non-small cell lung cancers, most often in the adenocarcinoma subtype.

PMID 21102257 · Marcus et al., 2010 · Open in CIViC